Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...

Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Myers Squibb (BMY) is a contrarian value play with a 5.39% dividend yield, strong growth strategy, and long-term potential.

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Bristol-Myers Squibb Company (BMY) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.46, which comfortably ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...